Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results

Hims & Hers Health (NYSE:HIMS) posted its quarterly earnings data on Monday. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26, Briefing.com reports. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the company earned ($0.04) EPS. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Stock Performance

HIMS traded up $0.11 on Tuesday, hitting $20.87. The company had a trading volume of 34,408,063 shares, compared to its average volume of 8,451,947. The stock has a market capitalization of $4.48 billion, a price-to-earnings ratio of 271.03 and a beta of 1.06. The stock has a fifty day moving average price of $18.10 and a 200-day moving average price of $18.19. Hims & Hers Health has a 12-month low of $6.23 and a 12-month high of $25.74.

Insider Activity

In related news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares in the company, valued at $2,341,011.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25. Following the sale, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the transaction, the chief financial officer now owns 145,763 shares of the company’s stock, valued at $2,960,446.53. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 650,659 shares of company stock worth $11,712,198. Corporate insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on HIMS shares. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. TD Cowen raised their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. Truist Financial upped their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Piper Sandler reiterated a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.